Dendrite Completes Scheduled Rollouts for Two Major Japanese Pharmaceutical Companies; Mitsubishi-Tokyo Pharmaceuticals Among Successful Rollouts.

Business Editors and Medical/Health Writers

MORRISTOWN, N.J.--(BUSINESS WIRE)--January 11, 2000

Dendrite International, Inc. (NASDAQ/NMS:DRTE) today announced that it has completed rollouts of the sales force effectiveness provider's J-Force system to Mitsubishi-Tokyo Pharmaceuticals in addition to the Japanese division of another leading global pharmaceutical company. These two Japanese pharmaceutical companies began their implementations of J-Force in 1999.

Over 700 sales representatives, managers, and users from Mitsubishi-Tokyo Pharmaceuticals and more than 1200 from the additional company are benefiting from J-Force, one of Dendrite's most cutting edge software offerings designed specifically for the Japanese pharmaceutical marketplace.

"Both companies chose Dendrite's J-Force over competing systems after thoughtful consideration, and we are pleased to solidify these relationships by completing the J-Force rollouts within the scheduled timeframes," said Dendrite Chairman and CEO John Bailye. "I am confident that successful and rapid implementations such as these will allow Dendrite to continue building upon our presence in the Japanese pharmaceutical marketplace."

Dendrite presently provides software and support services to thousands of sales representatives in Japan from companies such as Takeda, Kissei, Schering Plough, Parke-Davis, and Astra among others.

ABOUT MITSUBISHI-TOKYO PHARMACEUTICALS INC.

Tokyo Tanabe Co., Ltd and Mitsubishi Chemical Corporation  reached a basic agreement to merge on October 1, 1999. The merger is intended to reinforce the base of the two companies' pharmaceutical businesses, which are to be consolidated and operated by a wholly owned subsidiary of the merged company (i.e., Mitsubishi Chemical Corporation).

Tokyo Tanabe Co., Ltd, since its founding in 1901, has grown and prospered over its nearly hundred year history as a middle-tier pharmaceutical company that has introduced a wide variety of highly evaluated products for the digestive and respiratory organs, including URSO(R) and SURFACTEN(R).

Pharmaceutical business of Mitsubishi Chemical Corporation began in 1971, and their new products are extending into cardiology and the central nervous system. Major products in this area are THODUR(R) and ANPLAG(R)

ABOUT DENDRITE

As a leading global provider of highly specialized, integrated product and service offerings for the Pharmaceutical and Consumer Package Goods (CPG) industries, Dendrite supports corporate strategies for a sustained competitive advantage. Thousands of sales representatives and their managers from over 150 companies and 57 countries rely on Dendrite for a uniquely tailored combination of tools, information and skills to help them prepare for tomorrow's challenges and improve their sales success. Focusing strongly on outcomes, Dendrite combines its modular software products with specifically tailored coaching and support services. With a global infrastructure as its foundation, Dendrite's commitment to unparalleled service has been the hallmark of the business and the basis of strong customer loyalty since the Company's inception in 1986.

Headquartered in Morristown, New Jersey, Dendrite employs over 1200 people around the world. For more information, visit the Company's Web site at http://www.drte.com.

Note: Dendrite is a registered trademark of Dendrite International, Inc.

This press release contains statements that are forward-looking statements and discuss expectations about future events or outcomes with respect to Dendrite and its business, including statements regarding expected results for future periods. We believe these statements are within the scope of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that these statements be covered by the safe harbors created by such acts. The forward-looking statements are based on our current expectations, assumptions, estimates and projections about our company and the pharmaceutical and consumer packaged goods industries and involve risks and uncertainties. Accordingly, Dendrite's actual results may differ materially from the results discussed in or implied by such forward-looking statements. The risk factors that could cause actual results to differ from the results expressed or implied by these forward-looking statements include the following: (i) our business is heavily dependent on the pharmaceutical industry; (ii) our quarterly results of operations may fluctuate significantly and may not meet market expectations; (iii) our lengthy sales and implementation cycles make it difficult to predict our quarterly revenues; (iv) our fixed costs may lead to fluctuations in our quarterly operating results if revenues fall below expectations; (v) our business is affected by variations in our customers' budget cycles; (vi) our revenues would decline and our business would be adversely affected by the loss of one of our major customers; (vii) we may be unable to successfully introduce new products or respond to technological change; (viii) we are exposed to risks associated with the Year 2000 (for example, (a) demand for our software products and services may decline before and after the Year 2000, (b) our Year 2000 remediation efforts may be unsuccessful and (c) we may incur material expenses in connection with any claim relating to Year 2000 compliance of our own products or the products of third parties); (ix) increased competition may result in price reductions and decreased demand for our products and services; (x) some of our customers rely on our competitors for market data; (xi) our international operations have risks that our domestic operations do not; (xii) our success depends on retaining our key senior management team and on attracting and retaining qualified personnel; (xiii) our inability to manage our growth could adversely affect our business; (xiv) our business depends on proprietary technology that we may not be to protect completely; and (xv) the consumer packaged goods industry may have different characteristics from those we are used to in the pharmaceutical industry. In light of the significant uncertainties inherent in these forward-looking statements, you should not consider their inclusion as a representation by us or anyone else that we will achieve our objectives and plans. Moreover, we assume no obligation to update these forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. For further discussion of these and other factors that could adversely affect Dendrite's financial condition and results of operations consult Dendrite's annual report on Form 10-K and quarterly reports on Form 10-Q filed with the Securities and Exchange Commission.